Marker Therapeutics Announced Non-clinical Data Of Its Lead Multi-Tumor-Associated Antigen (multiTAA)-Specific T Cell Product Candidate, MT-401, In An Off-The-Shelf Setting And Provided An Update On Clinical Readiness For The Off-The-Shelf Program
Portfolio Pulse from Benzinga Newsdesk
Marker Therapeutics has announced non-clinical data for its lead multi-tumor-associated antigen (multiTAA)-specific T cell product candidate, MT-401, in an off-the-shelf setting. The company also provided an update on the clinical readiness for the off-the-shelf program.
August 07, 2023 | 11:36 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Marker Therapeutics' announcement of non-clinical data for MT-401 and updates on clinical readiness could potentially impact the company's stock.
The announcement of non-clinical data for a lead product candidate and updates on clinical readiness are significant events for a biotech company like Marker Therapeutics. This could potentially lead to increased investor interest and impact the company's stock positively in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100